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The diversity of the human leukocyte antigen (HLA) class I and II alle-les can be simplified by consolidating them into fewer supertypesbased on functional or predicted structural similarities in epitope-
binding grooves of HLA molecules. We studied the impact of matched and
mismatched HLA-A (265 versus 429), -B (230 versus 92), -C (365 versus 349),
and -DRB1 (153 versus 51) supertypes on clinical outcomes of 1934 patients
with acute leukemias or myelodysplasia/myeloproliferative disorders. All
patients were reported to the Center for International Blood and Marrow
Transplant Research following single-allele mismatched unrelated donor
myeloablative conditioning hematopoietic cell transplantation. Single mis-
matched alleles were categorized into six HLA-A (A01, A01A03, A01A24,
A02, A03, A24), six HLA-B (B07, B08, B27, B44, B58, B62), two HLA-C (C1,
C2), and five HLA-DRB1 (DR1, DR3, DR4, DR5, DR9) supertypes.
Supertype B mismatch was associated with increased risk of grade II-IV
acute graft-versus-host disease (hazard ratio =1.78, P=0.0025) compared to
supertype B match. Supertype B07-B44 mismatch was associated with a
higher incidence of both grade II-IV (hazard ratio=3.11, P=0.002) and III-IV
(hazard ratio=3.15, P=0.01) acute graft-versus-host disease. No significant
associations were detected between supertype-matched versus -mis-
matched groups at other HLA loci. These data suggest that avoiding HLA-
B supertype mismatches can mitigate the risk of grade II-IV acute graft-ver-
sus-host disease in 7/8-mismatched unrelated donor hematopoietic cell
transplantation when multiple HLA-B supertype-matched donors are avail-
able. Future studies are needed to define the mechanisms by which super-
type mismatching affects outcomes after alternative donor hematopoietic
cell transplantation. 
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ABSTRACT
Introduction
Cellular immune responses are mediated in part by
cytotoxic T lymphocytes that recognize peptide mole-
cules bound to human leukocyte antigen (HLA) on the sur-
face of antigen-presenting cells. HLA molecules are
extremely polymorphic1 and most of their variation is cen-
tered within the peptide-binding grooves that accommo-
date the primary anchor positions of the peptides dis-
played for immune recognition.2 Discovery of HLA super-
types almost a decade ago offered a simplification of
diverse HLA nomenclature by consolidating individual
HLA class I and II alleles into fewer supertype clusters
based on functional or predicted structural similarities in
epitope-binding specificities of HLA molecules.3 HLA alle-
les belonging to each particular supertype have either
experimentally proven or predicted ability to present anti-
genic peptides with similar anchoring amino acids at the
second (B-pocket) and C-terminal (F-pocket) positions of
the peptide molecules.4 Although HLA class I and II super-
types have been increasingly studied in association with
immune susceptibility to infection5-7 and cancer,8,9 the sig-
nificance of individual allele mismatching within and out-
side of HLA class I or II supertypes remains unknown in
the context of allogeneic hematopoietic cell transplanta-
tion (alloHCT). 
Recent encouraging outcomes in fully HLA-matched
unrelated donor (MUD) HCT10,11 have contributed in part
to the steady rise of MUD allografts that now outnumber
related donor transplants reported annually to the Center
for International Blood and Marrow Transplant Research
(CIBMTR).  Allografts mismatched at a single HLA-A, -B,
-C, or -DRB1 locus [i.e. 7/8 mismatched unrelated donor
(MMUD) HCT] were previously reported to be associated
with lower overall and disease-free survival, higher treat-
ment-related mortality, and more acute graft-versus-host
disease (GVHD) compared to outcomes of 8/8 MUD allo-
grafts.12-14 Despite these risks, 7/8 MMUD grafts remain a
viable option for HCT, particularly in minorities who lack
suitable donors or in patients with aggressive hematologic
malignancies for whom the risks of disease progression
due to delays in identifying optimal donors15 is offset in
part by the benefits of earlier transplantation with a 7/8
MMUD alloHCT.
Although multiple strategies have been sought to iden-
tify “permissible mismatches” associated with improved
outcomes of a single-allele MMUD HCT,13,16-19 the clinical
significance of clustering mismatched alleles within HLA
class I or II supertypes has not been established. We there-
fore conducted a large registry analysis of the CIBMTR
database of single-allele mismatched myeloablative allo-
grafts to determine whether HLA class I or II supertype
mismatching is associated with worse outcomes after 7/8
MMUD alloHCT.
Methods
Study design and patient selection
The study base population consisted of 2218 recipients of mye-
loablative conditioning followed by 7/8 HLA MUD bone marrow
or peripheral blood stem cell allografts for acute myeloid
leukemia, acute lymphoblastic leukemia, chronic myeloid
leukemia, and myelodysplastic syndrome between 1999 and 2011.
The patients’ data were reported to the National Marrow Donor
Program (NMDP)/CIBMTR, and subjects were excluded if: (i) they
did not consent to participate (n=55); (ii) they had fewer than 100
days of post-transplant follow up (n=11); (iii) their disease status
prior to alloHCT was missing (n=32); or (iv) they had undergone
ex vivo T-cell depletion (n=186). Recipients of prior HCT were
excluded. Allografts performed for lymphoid malignancies and
non-malignant disorders were also excluded in order to enhance
the overall homogeneity of the study population. All eligible adult
and pediatric study participants (n=1934) from 175 transplant cen-
ters and 16 countries provided informed consent to participate in
NMDP/CIBMTR research. This was a retrospective observational
study approved by NMDP/CIBMTR’s Institutional Review Board.
Standard methods of NMDP/CIBMTR data analysis were used to
mitigate any bias related to exclusion of non-consenting study
candidates.12 
HLA class I and II typing and supertype assignment
High-resolution allele-level typing at HLA-A, -B, -C, and -DRB1
loci was performed through the NMDP’s high-resolution HLA
typing project according to well established and validated DNA-
based techniques as previously reported.20 Single allele mismatch
at HLA-A, -B, -C, or -DRB1 was defined as a “7/8 match”. The
assignment algorithm for HLA-A and -B supertypes (Online
Supplementary Table S1) was based on an updated supertype clas-
sification with revised main HLA anchor specificities.21 This
method extends the previously described nine HLA-A and -B
supertype designations3 (A1, A2, A3, A24, B27, B44, B58, and B62)
to 12 supertype groups (A01, A01A03, A01A24, A02, A03, A24,
B07, B08, B27, B44, B58, B62), mostly due to the fact that certain
HLA-A alleles were found to have peptide-binding repertoires
with overlapping supertype specificities thereby resulting in
newly defined A01A03 and A01A24 supertype categories. This
revised classification of HLA-A and -B supertypes captured 99% of
the allelic diversity of allograft recipients and their donors. The
remaining 1% of unclassified HLA-A and -B alleles were grouped
into supertypes using bioinformatics methods.22 Two HLA-C
supertypes (C1 and C2) were derived from hierarchical cluster
analysis22 with distinct amino-acid fingerprints in protein structure
for HLA-C1 (Ser77) and -C2 (Asn77), which also coincide with killer
Ig-like receptor binding specificities for HLA-C.23 The grouping of
HLA-DRB1 alleles into supertypes was accomplished according to
previously described in-silico methods on the basis of common
structural and functional features of HLA class II molecules.24 The
significance of alternative supertype designations and individual
supertype effects was further assessed in the post-hoc exploratory
analysis. 
Study endpoints
The primary comparison between the 7/8 supertype-matched
and 7/8 supertype-mismatched allografts was conducted across
major clinical endpoints including overall survival, disease-free sur-
vival, relapse, treatment-related mortality, acute GVHD, chronic
GVHD, and time-to-neutrophil recovery (absolute neutrophil
count ≥ 0.5x109/L). Overall survival corresponded to the time from
transplantation to death from any cause and surviving patients
were censored at the time of their last follow-up. Disease-free sur-
vival was defined as the time between transplantation and relapse
or death from any cause; patients who remained alive and in
remission were censored at the time of their last follow-up.
Clinical relapse of the primary disease and treatment-related mor-
tality were defined by established CIBMTR criteria with the latter
defined as death while in continuous remission. Relapse was
therefore considered a competing risk endpoint for treatment-
related mortality, and treatment-related mortality was considered
a competing risk for relapse. The onset of grades II-IV or III-IV
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acute GVHD was determined based on the Consensus criteria25
while the onset of chronic GVHD was determined based on the
Seattle criteria.26 Neutrophil engraftment was defined as time-to-
neutrophil recovery. Death was considered a competing risk end-
point for engraftment and GVHD. 
Statistical analysis
Descriptive frequency estimates and comparisons for HLA alle-
les and supertypes as well as non-HLA study variables were
obtained through the standard methods of categorical and contin-
uous data analysis. Univariate probabilities for overall and disease-
free survival were calculated using the Kaplan-Meier estimator,27
whereas probabilities of treatment-related mortality, relapse, acute
GVHD, chronic GVHD, and neutrophil engraftment were calcu-
lated as cumulative incidence rates while accounting for compet-
ing risks.28 Survival curves were compared by the log-rank test.
Multivariate models for overall survival, disease-free survival,
relapse, treatment-related mortality, acute GVHD, chronic GVHD
and neutrophil engraftment were built using Cox proportional
hazards models. All clinical variables were tested for the affirma-
tion of the proportional hazards assumption. Variables that were
found to violate this assumption were adjusted for by stratifica-
tion. Final outcome-specific models were developed using a step-
wise model building procedure with the threshold of α=0.05 for
both entry and retention of co-variates in the model. Main vari-
ables, including HLA supertypes, were forced into the models
with the interactions between the main variables and the adjusted
covariates being tested at the significance level of α=0.01. Given
the multiple testing, P values <0.01 were considered statistically
significant.
Results 
HLA class I and II alleles and supertypes
For 1934 recipients of 7/8 MMUD alloHCT, single-allele
mismatches occurred within the HLA-A (36%), -B (17%), -
C (37%), and -DRB1 (11%) loci. Individual HLA-A, -B, -C,
and -DRB1 allele-level mismatches were matched by cor-
responding HLA supertypes in 38%, 71%, 51%, and 75%,
respectively (Table 1). Overall, supertype-level matching
at any one of the four HLA loci was observed in 52% of
study subjects.
Non-HLA characteristics
Baseline patient and clinical characteristics are summa-
rized in Table 2. In brief, the patients’ median age was 35
years (range, 1-70), and less than 20% of the study popu-
lation was of non-Caucasian background. Acute myeloid
leukemia and acute lymphoblastic leukemia accounted for
76% of all hematologic malignancies with over half of
patients classified as having intermediate or advanced risk
disease. Peripheral blood stem cell allografts were used in
56% of all transplant procedures. Conditioning regimens
for alloHCT included total body irradiation in 58% of
cases, whereas anti-thymocyte globulin or alemtuzumab
was incorporated into conditioning regimens in 36% of
cases. The majority of GVHD prophylactic regimens
included tacrolimus (62%) or cyclosporine (36%). The
median follow-up of surviving patients was 54 months
(range, 3-149) after alloHCT. In the crude comparisons of
supertype-matched (any locus) versus –mismatched 7/8
allografts, significant differences were observed in under-
lying hematologic malignancies, conditioning regimens
and timing of alloHCT (all P<0.01). Specifically, the super-
type-matched group contained a greater proportion of
total body irradiation-based conditioning regimens (62%
versus 54%, P<0.001) and a smaller proportion of in vivo T-
cell-depleted grafts (32% versus 40%, P<0.001). Supertype-
mismatched grafts were also more common in recent
years (P<0.001).
HLA supertype-matched and -mismatched outcomes
Univariate analyses of post-transplant outcomes based
on HLA supertype matching are summarized in Table 3.
Recipients of HLA supertype B-mismatched allografts
(n=62) had a significantly higher cumulative incidence of
grade II-IV acute GVHD than did recipients of HLA-B
supertype-matched (n=174) allografts (67% versus 47%,
respectively) (Figure 1, log-rank P=0.007). This association
was primarily driven by an excess in grade II acute GVHD
as no difference was found in the incidence of severe
grade III-IV acute GVHD with supertype-B mismatching.
The independent effect of HLA-B supertype matching on
grade II-IV acute GVHD was confirmed by the multivari-
able analysis [hazard ratio (HR)=1.78; 95% confidence
interval (CI), 1.23-2.59; P=0.0025] adjusting for age, gen-
der, disease type, ABO-mismatch, graft source, and in vivo
T-cell depletion (Figure 3). No other class I supertype mis-
match (including supertype mismatch at any locus) was
found to be significantly associated with any of the study
endpoints (engraftment, chronic GVHD, relapse or death)
at the pre-specified statistical threshold.  
HLA-B supertype mismatches involving B07-B44, B27-
B44, and B07-B62 were found to be the most prevalent
and these individual mismatches were subsequently
examined in the post-hoc analysis for their association with
acute GVHD. In contrast to all other HLA-B mismatched
supertypes, B07-B44 mismatched allografts were associat-
ed with a higher incidence of both grade II-IV (HR=3.11;
95% CI, 1.54-6.28, P=0.002) and III-IV acute GVHD
(HR=3.15; 95% CI, 1.30-7.65, P=0.01). 
HLA supertype matching in alloHCT
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Table 1. HLA class I/II allele- and supertype-level distribution.
Single allele-mismatch N HLA supertype
Matched (%) Mismatched (%)
HLA-A 694 265 (38.2) 429 (61.8)
HLA-B 322 230 (71.4) 92 (28.6)
HLA-C 714 365 (51.1) 349 (48.9)
HLA-DRB1 204 153 (75) 51 (25)
Any allele 1934* 1000 (51.7) 921 (48.3)
*Missing supertype assignment for 13 patients.
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Table 2. Non-HLA characteristics of the study population.
Characteristic All Supertype-matched Supertype-mismatched P value
Number of patients 1934* 999 922
Number of centers 175 161 148
Age, median (range), years 35 (1-70) 35 (1-69) 37 (1-70) 0.16
Age at alloHCT, years 0.51
<18 years old 410 (21%) 212 (21%) 194 (21%)
19-35 years old 541 (28%) 292 (29%) 246 (27%)
36-55 years old 758 (39%) 386 (39%) 367 (40%)
>55 years old 225 (12%) 109 (11%) 115 (12%)
Gender 0.95
Male 1090 (56%) 563 (56%) 521 (57%)
Female 844 (44%) 436 (44%) 401 (43%)
KPS prior to alloHCT 0.11
< 90 510 (26%) 259 (26%) 248 (27%)
90-100 1303 (67%) 666 (67%) 627 (68%)
Missing 121 (6%) 74 (7%) 47 (5%)
Race of recipient 0.12
Caucasian 1574 (81%) 824 (82%) 740 (80%)
African-American 175 (9%) 75 (8%) 100 (11%)
Asian / Pacific Islander 62 (3%) 35 (4%) 27 (3%)
Hispanic 71 (4%) 41 (4%) 28 (3%)
Native American 52(3%) 7 (<1%) 7 (<1%)
CMV Donor/Recipient 0.43
D-/R- 533 (28%) 294 (29%) 235 (25%)
D-/R+ 602 (31%) 300 (30%) 298 (32%)
D+/R- 272 (14%) 137 (14%) 133 (14%)
D+/R+ 499 (26%) 254 (25%) 242 (26%)
Disease 0.006
Acute myeloid leukemia 870 (45%) 427 (43%) 436 (47%)
Acute lymphoblastic leukemia 609 (31%) 345 (35%) 262 (28%)
Chronic myeloid leukemia 274 (14%) 147 (15%) 124 (13%)
Myelodysplastic syndrome 181 (9%) 80 (8%) 100 (11%)
Disease risk¥ 0.03
Early 813 (42%) 447 (45%) 362 (39%)
Intermediate 612 (32%) 310 (31%) 298 (32%)
Advanced 509 (26%) 242 (24%) 262 (28%)
Donor parity 0.03
Male or non-parous female 1389 (72%) 692 (69%) 688 (75%)
Parous female 443 (23%) 246 (25%) 193 (21%)
Missing 102 (5%) 61 (6%) 41 (4%)
Donor/Recipient sex match 0.43
Male / male 657 (34%) 329 (33%) 325 (35%)
Male / female 467 (24%) 233 (23%) 228 (25%)
Female / male 433 (22%) 234 (23%) 196 (21%)
Female / female 377 (19%) 203 (20%) 173 (19%)
Graft source 0.12
Bone marrow 845 (44%) 452 (45%) 385 (42%)
Peripheral blood stem cells 1089 (56%) 547 (55%) 537 (58%)
Conditioning with TBI 1127 (58%) 623 (62%) 498 (54%) <0.001
In vivo T-cell depletion§ 693 (36%) 316 (32%) 372 (40%) <0.001
GVHD prophylaxis 0.64
Tacrolimus-based 1193 (62%) 625 (63%) 560 (61%)
Cyclosporin A-based 689 (36%) 346 (35%) 338 (37%)
Other‡ 52 (3%) 28 (3%) 24 (3%)
Year of alloHCT <0.001
1999-2002 405 (21%) 234 (23%) 167 (18%)
2003-2006 633 (33%) 351 (35%) 278 (30%)
2007-2011 896 (46%) 414 (41%) 477 (52%)
Follow up, median (range), months 54 (3-149) 60 (3-149) 48 (3-145)
alloHCT: allogeneic hematopoietic cell transplantation; CMV: cytomegalovirus; D: donor; R: recipient; TBI: total body irradiation; GVHD: graft-versus-host disease; KPS: Karnofsky per-
formance score; *Including 13 cases with missing supertypes. ¥According to ASBMT 2006 definitions. §Antithymocyte globulin or alemtuzumab. ‡Mycophenolate mofetil + other
(n=5); methotrexate + other (n=10); antithymocyte globulin ± corticosteroid (n=6); sirolimus (n=1); unknown (n=30).
Since the impact of single-allele mismatching was most
apparent in patients with early and intermediate risk dis-
ease, as demonstrated in the prior large NMDP analysis,
we analyzed the effect of HLA-B supertype mismatching
within the subset of patients with early and intermediate
risks. Similar to our major finding, compared to HLA-B-
matched supertype grafts, HLA-B-mismatched supertype
grafts were associated with an increased risk of grade II-IV
acute GVHD (HR=1.84; 95% CI, 1.20-2.84, P<0.01). 
Although HLA-DRB1 supertype-mismatched trans-
plants (n=51) were associated with faster neutrophil
engraftment (median 12 versus 16 days, Figure 2), this early
difference in engraftment kinetics was not evident by day
28 after the transplant (94% versus 90%, P=0.4). Notably,
the relatively slower neutrophil engraftment among HLA-
DRB1 supertype-matched allograft recipients had no
adverse influence on treatment-related mortality or other
major post-transplant outcomes. On the contrary, mis-
matching at HLA-DRB1 supertypes was associated with a
trend towards higher treatment-related mortality
(HR=1.64; 95% CI, 0.99-2.74, P=0.057) and inferior overall
survival (HR=1.58; 95% CI 1.04-2.38, P=0.037) compared
to that associated with HLA-DRB1 supertype-matched
allografts.
Discussion 
In this large registry analysis of the CIBMTR database of
single allele mismatched myeloablative allografts, we
found a significant increase in the hazard of grade II-IV
acute GVHD among HLA-B supertype-mismatched com-
pared to HLA-B supertype-matched recipients of 7/8
MMUD allografts. Allele-level 7/8 HLA-B mismatch was
proven in the past to be associated with a higher incidence
of acute GVHD compared to 8/8 HLA-match [estimated
28% (95% CI, 26%-30%) incidence of grade III-IV acute
GVHD].12 In our cohort, the cumulative incidence rates of
grades II-IV and  III-IV acute GVHD among HLA-B allele-
MMUD allograft recipients were 53% (95% CI, 48%-
59%) and 31% (95% CI, 25%-37%), respectively. This
study has further extended the significance of HLA-B mis-
match in regards to acute GVHD at the supertype level for
7/8 allele-mismatched allografts. This observation con-
forms to our primary hypothesis of adverse post-trans-
plant outcomes with mismatched HLA supertypes and it
further supports the notion of increased alloreactivity with
HLA-B supertype-mismatched 7/8 MMUD transplants as
opposed to supertype-level mismatches at HLA-A, -C, or -
DRB1 loci. 
There are several possible explanations for our findings.
First, HLA-B alleles in humans have the highest degree of
described polymorphism relative to other class I or II alle-
les,29 likely as a result of the evolutionary pressures from
various infectious pathogens. The contribution of HLA
supertypes to immune-mediated responses against a num-
ber of viral infections was well established by prior
studies.5-7,30-32 It is therefore possible that early post-trans-
plant inflammatory responses mediated by mismatched
HLA-B supertypes could perpetuate alloreactive immune
responses such as acute GVHD. Although addressing this
hypothesis was beyond the scope of this study, this could
be tested in future studies. Second, it is possible that the
supertype categorization algorithm used in this study
could have obscured some of the underlying true associa-
tions between class I and II supertypes with major clinical
outcomes after alloHCT. Considerable diversity and a vari-
able degree of overlap exist between major HLA class I and
II supertype classifications. In this study we used the
revised supertype assignment algorithm proposed by Sette
and Sidney for HLA class I A- and B-supertypes.21 As
opposed to other alternatives,33-37 our chosen algorithm pro-
vided successful supertype classification for the entire
study population with most of the HLA-A and -B alleles
classified based on experimentally established motifs in
epitope-binding pockets of HLA molecules. Our supertype
assignment strategy therefore ensured the most stringent
selection of corresponding alleles, and by doing so it
strengthened the internal validity of the study. In addition,
our post-hoc exploratory analysis of alternative HLA-A, -B,
HLA supertype matching in alloHCT
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Table 3. Univariate probabilities of clinical outcomes between HLA supertype-matched (M) and –mismatched (MM) 7/8 unrelated donor allo-
grafts.
Outcomes Timing post-HCT HLA-A ST HLA-B ST HLA-C ST HLA-DRB1 ST Any HLA ST
M vs. MM M vs. MM M vs. MM M vs. MM M vs. MM
Acute GVHD II-IV Day 100 54% vs. 54% 47% vs.67% 51% vs. 48% 50% vs. 56% 51% vs. 53%
P=0.95 P=0.006 P=0.56 P=0.6 P=0.53
Acute GVHD III-IV Day 100 27% vs. 32% 31% vs. 32% 25% vs. 26% 22% vs. 22% 26% vs. 29% 
P=0.26 P=0.84 P=0.73 P=0.98 P=0.27
Any chronic GVHD  2 years 47% vs. 44% 51% vs. 42% 45% vs. 37% 43% vs. 46% 47% vs. 41%
P=0.39 P=0.14 P=0.03 P=0.78 P=0.012
ANC recovery Day 28 95% vs. 94% 94% vs. 95% 94% vs. 93% 91% vs. 94% 94% vs. 94% 
P=0.68 P=0.78 P=0.58 P=0.5 P=0.91
Treatment-related 3 years 45% vs. 40% 45% vs. 37% 37% vs. 40% 31% vs. 50% 40% vs. 40%
mortality P=0.19 P=0.25 P=0.42 P=0.03 P=0.89
Relapse 3 years 27% vs. 28% 20% vs. 26% 30% vs. 33% 27% vs. 19% 26% vs. 29% 
P=0.87 P=0.28 P=0.31 P=0.26 P=0.16
Disease-free 3 years 27% vs. 32% 35% vs. 37% 33% vs. 27% 42% vs. 31% 34% vs. 30%
survival P=0.23 P=0.81 P=0.06 P=0.2 P=0.14
Overall survival 3 years 31% vs. 38% 40% vs. 41% 39% vs. 30% 46% vs. 30% 38% vs. 35% 
P=0.09 P=0.88 P=0.02 P=0.05 P=0.12
ST: supertype; ANC recovery: absolute neutrophil count over 0.5x109/L.
and -DRB1 supertype classifications (data not shown)
revealed either limited capacity of other algorithms to clus-
ter allelic diversity of our study population into supertype
categories (e.g. the algorithms by Reche,37 Harjanto,34
Hertz/Yanover,35 and Greenbaum33), or significant overlap
between our supertype assignment algorithm and other
classifications such as those proposed by Lund36 or
Doytchinova.22 Furthermore, accounting for the mismatch
vector direction (i.e. graft-versus-host or host-versus-graft)
did not further influence or enrich the findings from this
study. 
Future practical implications of HLA-B supertype-
matched donor selection of 7/8 HLA-B MMUD allografts
can be expected to lower the incidence of grade II-IV acute
GVHD for a modest fraction (5%) of all 7/8 MMUD HCT
according to the donor selection practices reflected in this
study. Avoidance of B07-B44 supertype mismatches
should be interpreted with caution given the small num-
ber of allografts (n=9) in that subset analysis of the individ-
ual HLA-B supertype mismatches. Nevertheless, all but
one B07-B44 supertype mismatched allografts were com-
plicated by grade II-IV acute GVHD with over half classi-
fied as severe acute GVHD. 
Major limitations of this study are inherent to its retro-
spective design and in statistical challenges of analyzing
multiple endpoints across various HLA class I supertypes.
Consequently, we found faster neutrophil engraftment
among HLA-DRB1 supertype-mismatched allograft recip-
ients than among HLA-DRB1 supertype-matched allograft
recipients to be more controversial and difficult to explain.
Although recipients of HLA-DRB1 supertype-mismatched
allografts achieved neutrophil recovery on average 4 days
earlier, they demonstrated a trend towards inferior overall
survival. Notably, the median estimated time of neu-
trophil engraftment for DRB1-matched supertypes (16
days), which accounted for 75% of all 7/8 DRB1 allele-
mismatched allografts, was overall comparable to data
reported for 8/8 MUD HCT.38 In contrast, DRB1 supertype
A. Lazaryan et al.
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Figure 1. Cumulative incidence of grade
II-IV acute GVHD according to HLA-B
supertypes.
Figure 2. Neutrophil recovery according
to HLA-DRB1 supertypes.
mismatches accounted for only 2.6% of all 7/8 MMUD
HCT in this study thereby raising the possibility of a ran-
dom effect in lieu of a less plausible cause-and-effect rela-
tionship between DRB1 supertype mismatch and neu-
trophil engraftment kinetics. Further studies are needed to
provide definitive guidance on incorporating DRB1 super-
type matching in donor selection algorithms as increased
treatment-related mortality and inferior overall survival,
albeit not statistically significant in this dataset, are con-
cerning.
This large observational study has provided the first evi-
dence of “permissible” supertype-based donor selection of
optimal 7/8 MMUD for myeloablative alloHCT. Pending
validation in an independent  dataset, our findings suggest
that avoiding HLA-B supertype mismatch can serve as a
novel strategy to mitigate the risk of grade II-IV acute
GVHD in 7/8 MMUD HCT when multiple potential HLA-
B supertype-matched donors are available. This study
offers new insights and testable hypotheses for future
studies on the role of HLA supertypes among recipients of
reduced intensity MMUD HCT and recipients of other
mismatched alternative donor allografts such as umbilical
cord blood or haploidentical HCT.
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Figure 3. Multivariate analysis of the impact of supertype mismatching at HLA-A, -B, -C, and -DRB1. DFS: disease-free survival; TRM: treatment-related mortality;
aGVHD: acute graft-versus-host disease; cGVHD: chronic graft-versus-host disease; ANC>500: absolute neutrophil count > 0.5x109/L.
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